
Helps students see their full potential.
Makes learning interactive and fun.
A true gem in the academic community.
Brings real-world examples to learning.
Makes complex ideas simple and clear.
Dr Thomas Tapmeier is a Senior Research Fellow in the Department of Obstetrics and Gynaecology, School of Clinical Sciences at Monash Health, part of Monash University’s Faculty of Medicine, Nursing and Health Sciences. He joined in August 2020 as an internationally recognised researcher in experimental medicine and heads the Uterine Biology and Gynaecological Disease Group, focusing on endometriosis and uterine fibroids—gynaecological conditions affecting millions of women and causing severe pain, abnormal uterine bleeding, infertility, and miscarriages. Tapmeier obtained his Diplom in Human Biology from Philipps-Universität Marburg in 2003 and his PhD in Immunology from King’s College London in 2009, with a thesis titled 'The Role of T Cells in Renal Fibrosis'. His postdoctoral training in cancer immunology at the University of Oxford was funded by the Medical Research Council and Cancer Research UK. During this period, he improved the unilateral ureteric obstruction model of kidney disease in mice, developed an intravital imaging system to study vascular developments in tumours, and investigated pH low insertion peptide (pHLIP) probes as diagnostic tools in breast cancer models. From 2015 to 2019, he worked as a researcher for the Oxford–Bayer Alliance for Women’s Health at the Endometriosis CaRe Centre, Nuffield Department of Women’s & Reproductive Health, University of Oxford, where he contributed to new treatment avenues for endometriosis and uterine fibroids and authored the protocol for the longitudinal FENOX cohort study (ISRCTN 13560263, 2018–2028). Other appointments include Honorary Lecturer in Cancer Biology at the Australian National University (2019), Visiting Fellow at the University of Oxford (2019–present), and Honorary Research Associate in the Endometrial Stem Cell Biology group at the Hudson Institute of Medical Research.
Tapmeier’s research specializations include endometriosis, uterine fibroids, immunology, and cancer. Select key publications are 'Potential Role of Menstrual Fluid-Derived Small Extracellular Vesicle Proteins in Endometriosis Pathogenesis' (Gurung et al., 2025, Journal of Extracellular Vesicles), 'The role of small extracellular vesicle-miRNAs in endometriosis' (Nazri et al., 2023, Human Reproduction), 'Evolving polarisation of infiltrating and alveolar macrophages in the lung during metastatic progression of melanoma suggests CCR1 as a therapeutic target' (Tapmeier et al., 2022, Oncogene), 'Neuropeptide S receptor 1 is a nonhormonal treatment target in endometriosis' (2021, Science Translational Medicine), 'Characterization of exosomes in peritoneal fluid of endometriosis patients' (Nazri et al., 2020, Fertility and Sterility), and 'Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction' (Tapmeier et al., 2010, Kidney International). He has received the Sarah Agboolah Studentship for PhD studies, Amgen travel bursaries, funding for lab exchanges at TcLand (Nantes) and Bayer AG (Berlin), a grant for exosome research from the University of Oxford Medical Sciences Division, and an industry collaborative grant from the Oxford–Bayer Alliance investigating angiogenesis in uterine fibroids. Tapmeier is a named contributor to intellectual property and patents within the Alliance, serves as a peer reviewer for Fertility & Sterility, Journal of Extracellular Vesicles, Experimental and Molecular Pathology, and Journal of Translational Medicine, and is a member of the European Society of Human Reproduction and Embryology.